Corcept Therapeutics (CORT) Accumulated Expenses (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Accumulated Expenses data on file, last reported at $34.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 61.64% year-over-year to $34.1 million; the trailing twelve-month figure through Mar 2026 stood at $34.1 million (down 61.64% YoY), and the FY2025 full-year result was $90.6 million, changed 0.11% from the prior year.
• Accumulated Expenses declined to $34.1 million in Q1 2026, from $90.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $108.4 million in Q3 2025 to a low of $14.0 million in Q1 2023.
• A 5-year average of $59.3 million and a median of $59.2 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 327.32% in 2024 and sank 61.64% in 2026, its largest moves.
• Tracing CORT's Accumulated Expenses over 5 years: stood at $30.8 million in 2022, then soared by 67.63% to $51.6 million in 2023, then soared by 75.68% to $90.7 million in 2024, then slipped by 0.11% to $90.6 million in 2025, then slumped by 62.37% to $34.1 million in 2026.
• Business Quant data shows CORT's Accumulated Expenses at $34.1 million in Q1 2026, $90.6 million in Q4 2025, and $108.4 million in Q3 2025.